You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel immunotherapy strategy for treatment of pancreatic cancer
SBC: Oncotab, Inc. Topic: NCIDESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
SBC: 7 Hills Pharma LLC Topic: 102DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents
SBC: Capture Pharmaceuticals, Inc. Topic: 102DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Delivery of pathogen trapping antibodies for vaginal protection
SBC: MUCOMMUNE, LLC Topic: NIAIDDESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDDESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
SBC: CELL MICROSYSTEMS INC Topic: NIAIDPROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates
SBC: EVOKE MEDICAL LLC Topic: NIAMSDESCRIPTION provided by applicant The objective of this Phase I STTR research is to develop and test osteoinductive lumbar spinal fusion implant prototypes made using materials technology developments discovered by the PI at the University of Kansas In preliminary work lower impedance piezoelectric composite materials that generate power for direct current DC electrical stimulation applica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Blood based diagnostics for Alzheimer s Disease
SBC: Amprion, Inc. Topic: NIADESCRIPTION provided by applicant This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a blood test for Alzheimerandapos s disease AD diagnosis AD is the most common dementia in the elderly population and one of the leading causes of death in the developed world One of the main problems in AD is the lack of an early sensitive and objective ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NIADESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health